Evoke Pharma to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
September 09 2020 - 8:30AM
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
company focused on treatments for gastrointestinal (GI) diseases,
today announced that Dave Gonyer R.Ph., President and Chief
Executive Officer, and Matt D’Onofrio, Chief Business Officer, are
scheduled to participate virtually in the H.C. Wainwright 22nd
Annual Global Investment Conference taking place September 14 –
September 16, 2020.
Event: |
H.C. Wainwright 22nd Annual Global Investment Conference |
Format: |
Corporate Presentation and One-on-One Meetings |
Date: |
Monday, September 14, 2020 (presentation) |
Location: |
Virtual |
Time: |
2:00 pm ET (presentation) |
An audio webcast of the H.C. Wainwright
presentation will be available online at Evoke Pharma’s investor
relations website at www.evokepharma.com. Additionally, a replay
will be available for 90 days after the presentation. Investors
participating in the conference who would like to schedule a
one-on-one call with Evoke management may do so by contacting their
H.C. Wainwright representative, or Emma Poalillo of The Ruth Group
at epoalillo@theruthgroup.com.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company
focused primarily on the development of drugs to treat GI disorders
and diseases. The Company developed GIMOTI, a nasal spray
formulation of metoclopramide, for the relief of symptoms
associated with acute and recurrent diabetic gastroparesis in
adults.
Diabetic gastroparesis is a GI disorder
affecting millions of patients worldwide, in which the stomach
takes too long to empty its contents resulting in serious GI
symptoms as well as other systemic complications. The gastric delay
caused by gastroparesis can compromise absorption of orally
administered medications. Prior to FDA approval to commercially
market GIMOTI, metoclopramide was only available in oral and
injectable formulations and remains the only drug currently
approved in the United States to treat gastroparesis. Visit
www.EvokePharma.com for more information.
Investor ContactThe
Ruth GroupEmma PoalilloTel: 646-536-7024
epoalillo@theruthgroup.com |
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Apr 2023 to Apr 2024